Literature DB >> 26039935

Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.

Y Seino1, Y Ikeda2, E Niemoeller3, D Watanabe2, H Takagi2, D Yabe1, N Inagaki4.   

Abstract

The aim of the study was to evaluate the efficacy and safety of once-daily lixisenatide 20 μg as add-on to basal insulin with or without sulfonylurea in Asian patients with type 2 diabetes mellitus. The study as a subanalysis of the 159 Japanese patients from the 24-week double-blind GetGoal-L-Asia study (NCT00866658) who received once-daily lixisenatide or placebo. The primary endpoint was change from baseline in HbA1c evaluated using analysis of covariance. Once-daily lixisenatide significantly reduced mean HbA1c [least squares mean difference vs. placebo - 1.1% (- 12 mmol/mol); p<0.0001]. Significantly more patients in the lixisenatide group reached HbA1c targets of < 7% (53 mmol/mol; 31.4 vs. 2.3% for placebo; p<0.0001) and ≤ 6.5% (48 mmol/mol; 12.9 vs. 1.2% for placebo; p=0.0028). Lixisenatide significantly reduced 2-h postprandial plasma glucose (least squares mean difference vs. placebo-8.64 mmol/l; p<0.0001), glucose excursion (least squares mean difference vs. placebo - 7.80 mmol/l; p<0.0001) and fasting plasma glucose (least squares mean difference vs. placebo - 0.96 mmol/l; p=0.0126). Body weight was reduced with lixisenatide but with no significant difference vs. placebo. Gastrointestinal adverse events were more frequent with lixisenatide (61.1 vs. 11.5% for placebo) but were generally transient and mild-to-moderate in intensity. The incidence of symptomatic hypoglycemia was 39.0 vs. 13.5% in patients receiving sulfonylureas and 32.3 vs. 22.9% in those not receiving sulfonylureas, for lixisenatide and placebo, respectively. In Japanese patients with type 2 diabetes mellitus, once-daily lixisenatide was well tolerated and led to significant and clinically relevant improvement in glycemic control, with a pronounced effect on postprandial plasma glucose. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26039935     DOI: 10.1055/s-0035-1549875

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.

Authors:  Wenying Yang; Kyungwan Min; Zhiguang Zhou; Ling Li; XiangJin Xu; Dalong Zhu; A Venkateshwar Rao; Laxminarayanappa Sreenivasa Murthy; Nianxian Zhang; Ivy Li; Elisabeth Niemoeller; Shuhua Shang
Journal:  Diabetes Obes Metab       Date:  2017-10-05       Impact factor: 6.577

2.  Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.

Authors:  Yutaka Seino; Aleksandra Stjepanovic; Akane Takami; Hiroki Takagi
Journal:  J Diabetes Investig       Date:  2017-06-12       Impact factor: 4.232

3.  Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.

Authors:  Hiroaki Seino; Yukiko Onishi; Yusuke Naito; Mitsuhisa Komatsu
Journal:  Diabetol Metab Syndr       Date:  2016-06-01       Impact factor: 3.320

4.  Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.

Authors:  Yutaka Seino; Yasuo Terauchi; Xiangling Wang; Daisuke Watanabe; Elisabeth Niemoeller
Journal:  J Diabetes Investig       Date:  2017-06-12       Impact factor: 4.232

5.  Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.

Authors:  Melanie J Davies; Lawrence A Leiter; Bruno Guerci; George Grunberger; F Javier Ampudia-Blasco; Christine Yu; William Stager; Elisabeth Niemoeller; Elisabeth Souhami; Julio Rosenstock
Journal:  Diabetes Obes Metab       Date:  2017-07-07       Impact factor: 6.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.